Sayenko Kharenko antitrust team provided legal assistance to Nycomed A/S (“Nycomed”), Copenhagen, Denmark, in merger clearance with the Antimonopoly Committee of Ukraine (the "AMC") for Euro 9.6 billion acquisition of Nycomed by Takeda Pharmaceutical Company Limited (“Takeda”), a Japan-based pharmaceutical company.
The concentration will allow Takeda to transform its organization through the acquisition of Nycomed. Nycomed enables Takeda to maximize the value of its portfolio and gives the company an immediate strong presence in the high-growth emerging markets while doubling Takeda’s European sales.
Nycomed is a privately-owned pharmaceutical company with strong presence in Europe and emerging markets. Nycomed manufactures both established prescription pharmaceutical products and over the counter (OTC) products.
Takeda is a research-based global pharmaceutical company concentrating management resources on the core therapeutic areas of Metabolic, Oncology, CNS diseases and Immunology/ Inflammatory.
After the review of the proposed transaction, the AMC concluded that its implementation neither poses threats to competition nor significantly limits competition on any product market in Ukraine.
Sayenko Kharenko competition team for the current transaction included counsel Dmitry Taranyk and associate Maksym Nazarenko, led by partner Vladimir Sayenko.